We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Rapid Diagnostic Test to Tackle Fatal Sleeping Sickness

By LabMedica International staff writers
Posted on 27 Jan 2016
Print article
Image: The bite of an infected female tsetse fly taking a bloodmeal can transmit Trypanosoma brucei gambiense, cause of Human African Trypanosomiasis (HAT), also called African sleeping sickness, usually fatal if untreated  with patients falling into a coma before death (Photo David Bygott/Flickr, courtesy of Biotechnology and Biological Sciences Research Council (UK)).
Image: The bite of an infected female tsetse fly taking a bloodmeal can transmit Trypanosoma brucei gambiense, cause of Human African Trypanosomiasis (HAT), also called African sleeping sickness, usually fatal if untreated with patients falling into a coma before death (Photo David Bygott/Flickr, courtesy of Biotechnology and Biological Sciences Research Council (UK)).
Using an innovative approach, scientists have developed a simple serodiagnostic method, similar to a dipstick pregnancy test, to fight human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense. The new test requires only a pin-prick blood sample and will remove the need to take complex equipment into remote areas.

Although millions are at risk of contracting HAT, some at-risk areas remain uncovered by surveillance and control efforts. Existing tests for T. b. gambiense rely on samples extracted directly from this dangerous parasite. A research team, led by Dr Barrie Rooney and Prof. Mark Smales of the University of Kent (Kent, UK), has designed a safer, easier, faster (about half the time of traditional methods), and less costly method for preparing samples. Also, fewer people will be needed to administer the test.

This next-generation test is based on genetic engineering to express selected T.b. gambiense recombinant antigens in a safe, easy-to-grow strain of the non-human parasite Leishmania tarentolae.

The work is part of the Biotechnology and Biological Sciences Research Council (BBSRC)’s Flexible Interchange Program (FLIP) in a project with Medecins Sans Frontieres (MSF; Geneva, Switzerland). Dr Rooney said: “I have been involved with MSF mobile HAT screening teams in central African countries for over 10 years. Traditional testing involves a large team in remote areas doing time-consuming microscopic work, and painful lumbar punctures. For this you need electricity and refrigeration. By combining the latest genome databases and old fashioned fermentation techniques we have come up with a fast, simple way of making robust and reliable tests. The new tests are designed to be heat-stable and user-friendly, like a dipstick pregnancy test. It will be a major improvement for screening and treatment of this deadly disease and speed us on the way to ‘the elimination of sleeping sickness as a public health hazard’ which is a World Health Organization target.”

Prof. Melanie Welham, executive director, BBSRC, Science, said, “This is a brilliant example of exactly what the FLIP scheme is all about. FLIP funding allowed Dr Rooney to work with the University of Kent and MSF to design and develop this test in just 14 months. The promise and potential impact of this new diagnostic is obvious and I wish Dr Rooney success in the forthcoming work in the Democratic Republic of the Congo (DRC). FLIP brings scientists into different environments where they can learn new skills and exploit their existing expertise in new collaborations, enhancing the impact of bioscience research.”

In July, Dr Rooney traveled to DRC to identify areas where field trials of the new test could be carried out, alongside an MSF HAT mobile team. The method also has potential to be developed for diagnosis of other tropical diseases, such as Chagas disease (T. cruzi) and visceral leishmaniasis.

The study, by Rooney B et al., was published December, 2015, in the journal PLOS Neglected Tropical Diseases.

Related Links:

University of Kent
Biotechnology and Biological Sciences Research Council (BBSRC) 
Medecins Sans Frontieres


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hepatitis B Assay
Monolisa HBs Ag ULTRA Assay
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.